{"id":"placebo-for-e2-neta","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4107857","moleculeType":"Small molecule","molecularWeight":"457.84"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (estradiol/norethindrone acetate combination). It contains no active ingredients and serves as a baseline comparator to demonstrate that any observed clinical benefit is due to the active hormone therapy rather than non-specific effects.","oneSentence":"This is a placebo control arm with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:22.302Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 trial for estradiol/norethindrone acetate (E2/NETA) hormone replacement therapy"}]},"trialDetails":[{"nctId":"NCT03271489","phase":"PHASE3","title":"Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-09-13","conditions":"Heavy Menstrual Bleeding, Uterine Fibroids","enrollment":478},{"nctId":"NCT04335591","phase":"PHASE3","title":"Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2020-03-05","conditions":"Endometriosis","enrollment":356},{"nctId":"NCT04372121","phase":"PHASE3","title":"Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain","status":"TERMINATED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2020-03-23","conditions":"Endometriosis","enrollment":30},{"nctId":"NCT03992846","phase":"PHASE3","title":"Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2019-06-13","conditions":"Endometriosis","enrollment":486},{"nctId":"NCT03986944","phase":"PHASE3","title":"A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain","status":"TERMINATED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2019-05-23","conditions":"Endometriosis","enrollment":85},{"nctId":"NCT03213457","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-07-07","conditions":"Endometriosis","enrollment":681},{"nctId":"NCT03751124","phase":"PHASE3","title":"Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2018-10-16","conditions":"Uterine Leiomyoma, Uterine Fibroids","enrollment":229},{"nctId":"NCT01656434","phase":"PHASE3","title":"Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2012-11-02","conditions":"Contraception","enrollment":3173},{"nctId":"NCT03103087","phase":"PHASE3","title":"LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-06-14","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":382},{"nctId":"NCT03049735","phase":"PHASE3","title":"LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-04-26","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":388},{"nctId":"NCT02925494","phase":"PHASE3","title":"An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-09-14","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":433},{"nctId":"NCT02691494","phase":"PHASE3","title":"Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02-03","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":378},{"nctId":"NCT01441635","phase":"PHASE2","title":"Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-09-08","conditions":"Heavy Uterine Bleeding, Uterine Fibroids","enrollment":271},{"nctId":"NCT03204331","phase":"PHASE3","title":"SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-11-01","conditions":"Endometriosis Related Pain","enrollment":623},{"nctId":"NCT03204318","phase":"PHASE3","title":"SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-12-07","conditions":"Endometriosis Related Pain","enrollment":638},{"nctId":"NCT03070899","phase":"PHASE3","title":"Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"ObsEva SA","startDate":"2017-04-20","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":526},{"nctId":"NCT03070951","phase":"PHASE3","title":"Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"ObsEva SA","startDate":"2017-05-23","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":511},{"nctId":"NCT01817530","phase":"PHASE2","title":"Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-04-08","conditions":"Heavy Uterine Bleeding, Uterine Fibroids","enrollment":571},{"nctId":"NCT02654054","phase":"PHASE3","title":"Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-22","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":413}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for E2/NETA","genericName":"Placebo for E2/NETA","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control arm with no active pharmacological mechanism. Used for Control arm in phase 3 trial for estradiol/norethindrone acetate (E2/NETA) hormone replacement therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}